ReWalk Takes Another Step Toward Medicare Coverage
MARLBOROUGH, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd. (Nasdaq:RWLK) (“ReWalk”, or the “Company”), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, is announcing that the Company will begin submitting Medicare cases following CMS’s September 26, 2022, announcement affirming that the MACs have discretion to cover and reimburse for the ReWalk exoskeleton. ReWalk Robotics is actively engaged with CMS in its commitment to evaluate complex advanced technologies like exoskeletons.
Related news for (RWLK)
- ReWalk Robotics Transforms Company Identity, Rebrands as Lifeward
- Sidoti Events, LLC’s Virtual January Micro-Cap Conference
- ReWalk Robotics Reports First Quarter 2023 Financial Results
- Advancement in ReWalk Technology Achieves FDA Clearance as Only Personal Exoskeleton to Enable Use on Stairs and Curbs
- Germany’s second largest health insurer withdraws appeal with Federal Social Court, accepts prior ruling of exoskeletons as direct disability compensation